SEC Comment Letter 0000000000-24-009965 to Compass Therapeutics, Inc. (CMPX) (CIK 0001738021) (CMPX)
Compass Therapeutics, Inc. (CMPX) (CIK 0001738021)
Date: Sept. 3, 2024 · CIK: 0001738021 · Accession: 0000000000-24-009965
AI Filing Summary & Sentiment
File numbers found in text: 333-281891
Letter
September 3, 2024 Thomas Schuetz Chief Executive Officer Compass Therapeutics, Inc. 80 Guest Street Suite 601 Boston, Massachusetts 02135 Re:Compass Therapeutics, Inc. Registration Statement on Form S-3 Filed August 30, 2024 File No. 333-281891 Dear Thomas Schuetz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Finn Murphy
Show Raw Text
September 3, 2024
Thomas Schuetz
Chief Executive Officer
Compass Therapeutics, Inc.
80 Guest Street
Suite 601
Boston, Massachusetts 02135
Re:Compass Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 30, 2024
File No. 333-281891
Dear Thomas Schuetz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Finn Murphy